<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136676">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01322048</url>
  </required_header>
  <id_info>
    <org_study_id>110429</org_study_id>
    <nct_id>NCT01322048</nct_id>
  </id_info>
  <brief_title>DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury</brief_title>
  <official_title>DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Severe Traumatic Brain Injury, A Pilot Randomized Clinical Trial Using Propranolol and Clonidine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vanderbilt Institute for Clinical and Translational Research (CTSA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Association for the Surgery of Trauma (EAST)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators intend to determine the effect of adrenergic blockade on 1) short-term
      physiology, behavior, and cognition and 2) long-term neuropsychological outcomes after
      severe Traumatic Brain Injury (TBI).

      The primary hypothesis is that adrenergic blockade after severe TBI will be associated with
      increased ventilator-free days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe traumatic brain injury (TBI) is associated with sympathetic hyperactivity resulting
      in catecholamine excess, abnormal heart rate variability, agitation and sympathetic storms,
      deep white matter changes, and poor neuropsychological outcomes. Notably, persistent
      sympathetic hyperactivity after TBI results in higher days of mechanical ventilation and
      longer intensive care unit (ICU) length of stay (LOS). While there are data describing
      limited portions of this response, the full spectrum of sympathetic hyperactivity after
      severe TBI has not been systemically described or methodically intervened upon.

      We will perform a double-blinded, randomized, placebo-controlled pilot trial in a 100
      patient cohort in which one group will receive centrally acting sympatholytic drugs,
      propranolol and clonidine, and the other group, placebo, within 48 hours of severe TBI. The
      length of therapy will be 7 days.

      The primary question studied is whether ventilator-free days will be increased after
      therapy.

      Secondary endpoints include plasma and urine catecholamine levels, heart rate and blood
      pressure variability, responses to autonomic cold pressor testing, assessments of coma,
      sedation, and agitation, sedative requirements, analgesic use, antipsychotic medication use,
      coma-free days, ventilator-free days, Intensive Care Unit (ICU) length of stay, and
      survival. Also, neuropsychological outcomes will be measured at ICU discharge, 3 months, and
      12 months.

      Interim Analysis: At approximately 50% targeted accrual, n=46 randomized subjects, an
      interim analysis will be performed with A Priori (planned) futility and efficacy rules,
      which are DSMB and IRB approved.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>Baseline to hospital discharge (average t = Day 30)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Catecholamine Levels</measure>
    <time_frame>Baseline, Post-treatment (t=Day 8)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24h Urinary Catecholamine Levels</measure>
    <time_frame>Baseline, Post-treatment (t=Day 8)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily percentage of low heart rate variability (HRV) intervals</measure>
    <time_frame>Baseline to ICU Discharge (average t = Day 14)</time_frame>
    <description>Critically low range of HRV defined as 0.3 - 0.6 beats per minute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Low frequency to high frequency ratio from heart rate variability analysis</measure>
    <time_frame>Post-treatment (t= Day 8 )</time_frame>
    <description>Response to autonomic cold pressor testing after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RASS score</measure>
    <time_frame>Twice daily to hospital discharge (average t = Day 30)</time_frame>
    <description>Richmond Agitation-Sedation Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Agitation Behavior Scale (ABS) score</measure>
    <time_frame>Twice daily to hospital discharge (average t = Day 30)</time_frame>
    <description>Agitation Behavior Scale for TBI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow Coma Scale (GCS) score</measure>
    <time_frame>Twice daily to hospital discharge (average t = Day 30)</time_frame>
    <description>Glasgow Coma Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily pulse pressure variability</measure>
    <time_frame>Baseline to ICU discharge (average t = Day 14)</time_frame>
    <description>Standard deviation of the 5 minute means of pulse pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coma-free days</measure>
    <time_frame>Baseline to hospital discharge (average t = Day 30)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Length of Stay</measure>
    <time_frame>Baseline to ICU discharge (average t = Day 14)</time_frame>
    <description>Time to ICU discharge, represented by readiness for ICU discharge indicated by a physician order for transfer to a lower level of care even if a bed availability problems prevent actual discharge from the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Baseline to hospital discharge (average t = Day 30)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life after Brain Injury (QOLIBRI)</measure>
    <time_frame>3 months, 12 months</time_frame>
    <description>Quality of Life after Brain Injury (QOLIBRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extended Glasgow Outcome Scale (GOSE)</measure>
    <time_frame>At 3 months, 12 months</time_frame>
    <description>Assessment of mortality and disability in TBI patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Assessment</measure>
    <time_frame>At hospital discharge (average t = Day 30), 3 months, 12 months</time_frame>
    <description>Assessed using a battery of cognitive tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjunct medication use</measure>
    <time_frame>Baseline to hospital discharge (average t = Day 30)</time_frame>
    <description>quantification of beta-blockers, alpha-2-agonists, analgesics, sedatives, and antipsychotics used throughout hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Complications</measure>
    <time_frame>Baseline to ICU discharge (average t = Day 14)</time_frame>
    <description>Composite measure of any dysrhythmias (other than asymptomatic bradycardia and sinus tachycardia), myocardial infarction, and/or cardiac arrest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>3 months, 12 months</time_frame>
    <description>Assessment for Depression after TBI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rancho Los Amigos Level of Cognitive Functioning</measure>
    <time_frame>At hospital discharge (average t = Day 30)</time_frame>
    <description>Cognitive Function at Discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Blood Velocity</measure>
    <time_frame>Baseline, Post-treatment (t=Day 8)</time_frame>
    <description>Transcranial Doppler Sonogram of Cerebral Blood Velocity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Brain Injuries</condition>
  <condition>Craniocerebral Trauma</condition>
  <condition>Trauma, Nervous System</condition>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Adrenergic Blockade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propranolol and Clonidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Propranolol and Per Tube Clonidine</intervention_name>
    <description>1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days</description>
    <arm_group_label>Adrenergic Blockade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo IV q6h and Per Tube q12, both for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 16 years to 64 years

          -  Glasgow Coma Scale score less than or equal to 8 (Severe TBI) with injury on CT

          -  Screen within 24 hours of injury

        Exclusion Criteria:

          -  Pre-existing heart disease (i.e. coronary heart disease)

          -  Pre-existing cardiac dysrhythmia

          -  Allergy to study drugs

          -  Penetrating brain injury

          -  Pre-existing brain dysfunction (i.e. prior severe TBI, debilitating stroke)

          -  Impending brain herniation (i.e. loss of bilateral corneal reflexes)

          -  Craniectomy or craniotomy

          -  Spinal cord injury

          -  Myocardial injury

          -  Severe liver disease

          -  Current use of beta-blockers and/or alpha-2-agonist

          -  Withdrawal of care expected in 24 hours

          -  Prisoners

          -  Pregnant women

          -  Unable to follow-up through final visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mayur B Patel, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://medschool.mc.vanderbilt.edu/facultydata/php_files/show_faculty.php?id3=18283</url>
    <description>Principal Investigator</description>
  </link>
  <link>
    <url>http://www.vanderbilthealth.com/traumasurvivors/36172</url>
    <description>Vanderbilt Multidisciplinary Traumatic Brain Injury Clinic (MTBIC)</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 27, 2017</lastchanged_date>
  <firstreceived_date>March 2, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Mayur Patel</investigator_full_name>
    <investigator_title>Assistant Professor of Surgery and Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>Sympathetic Hyperactivity</keyword>
  <keyword>Traumatic Brain Injury</keyword>
  <keyword>Agitation</keyword>
  <keyword>Severe TBI</keyword>
  <keyword>TBI</keyword>
  <keyword>Catecholamines</keyword>
  <keyword>Heart rate variability</keyword>
  <keyword>Adrenergic alpha-Agonists</keyword>
  <keyword>Adrenergic beta-Antagonists</keyword>
  <keyword>Cognitive Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Craniocerebral Trauma</mesh_term>
    <mesh_term>Trauma, Nervous System</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenergic Agents</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
